Immatics Streamlines SUPRAME Trial, Reports $448M Cash and Strong ASCO Data
IMTX sits 83% above its 52-week low of $5.05 on elevated volume (2.3× avg).
Summary
Immatics reported Q2 2026 results with $448.2M in cash, runway into 2028, and a key SUPRAME trial design change: slower-than-modeled PFS events mean the company will skip the interim analysis and go straight to a single streamlined final analysis, with topline data now expected H1 2027 and BLA submission in 2027. Updated Phase 1b anzu-cel data at ASCO 2026 showed 56% cORR and 16.2 months mOS in metastatic melanoma, reinforcing the lead program's profile. The trial design change reduces near-term data catalysts but strengthens the final analysis and OS power, which the company frames as a more efficient path to approval. Watch for ESMO 2026 presentations of IMA203CD8 and IMA402 data, and the H1 2027 SUPRAME topline readout.
Updates
· SEC 6-K — The 6-K includes the interim report and investor presentation; cash and equivalents were €232.5M and short-term deposits €160.9M as of June 30, 2026.
At the time of this announcement, IMTX was trading at $9.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.05 to $12.41. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.